Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 1 - Studien 1 bis 10 von insgesamt 10
- Rekrutierung läuft
A Randomized, Open-label, Controlled Phase 3 Adaptive Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen Protocol Number 20120215 (ALL-Rez HR Rando HC3 vs Blin)
Molekulare Marker - Rekrutierung läuft
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CART Cell Therapy (PAVO)
Molekulare Marker - Rekrutierung läuftEfficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström's MacroglobulinemiaIndikationenMolekulare Marker
- Rekrutierung läuftPhase II Trial for the Treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential dose reduced chemotherapy and BlinatumomabMolekulare Marker
- Rekrutierung läuftA multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (Blast Successor Trial)Molekulare Marker
- Rekrutierung läuftA Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) (ZUMA-1)Molekulare Marker
- Rekrutierung läuftA Phase 2 Multicenter Study Evaluating the efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA 2)Molekulare Marker
- Rekrutierung läuftA phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the
efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus RCHOP
in previously untreated, high-intermediate and high-risk patients with newly diagnosed
diffuse large B-cell lymphoma (DLBCL)Molekulare Marker - Rekrutierung läuftEine nicht-interventionelle retrospektive Kohortenstudie zu systemischen Therapien bei rezidiviertem oder refraktärem diffusem grosszelligen B-Zell Lymphom für den Vergleich mit der Wirksamkeit von Tafasitamab+LenalidomidMolekulare Marker
- Rekrutierung läuftStudie zur Therapieoptimierung der HaarzellenleukämieMolekulare Marker